Final Results from KEYNOTE-100 Show Promise for Pembrolizumab Monotherapy

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes:

Treatment with pembrolizumab (brand name Keytruda) on its own shows modest responses in patients with recurrent ovarian cancer.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.